Bryan Iorgulescu, MD, MPH, FCAP

Peer-Reviewed Articles

1. Zhou T, Short NJ, Jain N, Patel KP, Jabbour EJ, Kantarjian HM, Medeiros LJ, Iorgulescu JB. Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data. Leukemia 39(7):1769-1772, 2025. e-Pub 2025. PMID: 40275068.
2. Ronaghy, A, Crimini, E, Holla, V, Mills Shaw, KR, Doefler, AM, Campbell, E, Yang, RK, Iorgulescu, JB, Patel, KP, McPherson, DD, Ning, J, Meric-Bernstam, F, Karp, DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025.
3. White MG, Ayabe RI, Zeineddine MA, Zeineddine FA, Yousef AMG, Yousef M, Galbraith NJ, Iorgulescu JB, Scally C, Fournier K, Newhook TE, You NY, Willis J, Kopetz S, Chang GJ, Shen JP, Uppal A. Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis. Transl Oncol 55:102379, 2025. e-Pub 2025. PMID: 40184716.
4. Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639(8054):474-482, 2025. e-Pub 2025. PMID: 39910301.
5. Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boelle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. J Clin Oncol 43(3):329-338, 2025. e-Pub 2025. PMID: 39356975.
6. Iorgulescu JB, Blewett T, Xiong K, Crnjac A, Liu R, Sridhar S, Braun DA, Sellars MC, Cheng J, Rhoades J, Reardon DA, Makrigiorgos GM, Wu CJ, Adalsteinsson VA. Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients. Clin Chem 71(1):215-225, 2025. e-Pub 2025. PMID: 39749509.
7. Iorgulescu, JB, Yang, RK, Roy Chowdhuri, S, Sura, GH. Same-day molecular testing for targetable mutations in solid tumor cytopathology—The next frontier of the rapid on-site evaluation. Cancer Cytopathology 133(1), 2025. e-Pub 2025. PMID: 39746874.
8. Lim-Fat, MJ, Wen, PY, Touat, M, Puduvalli, VK, Iorgulescu, JB. MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma. Neuro-oncology 26(12):2388-2390, 2024. e-Pub 2024. PMID: 39277807.
9. Subbiah, V, Gouda, MA, Iorgulescu, JB, Dadu, R, Patel, KP, Sherman, S, Cabanillas, ME, Hu, MI, Castellanos, LE, Amini, B, Meric-Bernstam, F, Shen, T, Wu, J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38438731.
10. Wan Q, Kim J, Lindsay C, Chen X, Li J, Iorgulescu JB, Huang RY, Zhang C, Reardon D, Young GS, Qin L. Auto-segmentation of Adult-Type Diffuse Gliomas: Comparison of Transfer Learning-Based Convolutional Neural Network Model vs. Radiologists. J Imaging Inform Med 37(4):1401-1410, 2024. e-Pub 2024. PMID: 38383806.
11. Lim-Fat, MJ, Iorgulescu, JB, Rahman, R, Bhave, V, Muzikansky, A, Woodward, E, Whorral, S, Allen, M, Touat, M, Li, X, Xy, G, Patel, J, Gerstner, E, Kalpathy-Cramer, J, Youssef, GC, Chukwueke, U, McFaline-Figueroa, JR, Nayak, L, Lee, EQ, Reardon, DA, Beroukhim, R, Huang, R, Bi, WL, Ligon, KL, Wen, PY. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma. Clinical Cancer Research 30(7):1327-1337, 2024. e-Pub 2024. PMID: 38252427.
12. Qin, X, Lam, A, Zhang, X, Sengupta, S, Iorgulescu, JB, Ni, H, Das, S, Rager, M, Zhou, Z, Zuo, T, Meara, GK, Floru, AE, Kemet, C, Veerapaneni, D, Kashy, D, Lin, L, Lloyd, K, Kwok, L, Smith, KS, Nagaraju, RT, Meijers, R, Ceol, C, Liu, CT, Alexandrescu, S, Wu, C, Keskin, DB, George, RE, Feng, H. CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness. Science Advances 10(11), 2024. e-Pub 2024. PMID: 38489372.
13. Russell, AJ, Weir, JA, Nadaf, NM, Shabet, M, Kumar, V, Kambhampati, S, Raichur, R, Marrero, GJ, Liu, S, Balderrama, KS, Vanderburg, CR, Shanmugam, V, Tian, L, Iorgulescu, JB, Yoon, CH, Wu, C, Macosko, EZ, Chen, F. Slide-tags enables single-nucleus barcoding for multimodal spatial genomics. Nature 625(7993):101-109, 2024. e-Pub 2024. PMID: 38093010.
14. Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest 133(22), 2023. e-Pub 2023. PMID: 37751299.
15. Iorgulescu JB, Shaw LK, Rashid A, Rao P, Mandayam S, Patel KP, Schmeler KM, Yang RK, Msaouel P. Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing. Curr Oncol 30(10):9019-9027, 2023. e-Pub 2023. PMID: 37887551.
16. Toker J, Iorgulescu JB, Ling AL, Villa GR, JAMA G, Parida L, Getz G, Wu CJ, Reardon DA, Chiocca EA, Mineo M. Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research 29(12):2226-2238, 2023. e-Pub 2023. PMID: 37053197.
17. Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, Brat DJ, Barnholtz-Sloan JS, Iorgulescu JB. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25(4):799-807, 2023. e-Pub 2023. PMID: 35994777.
18. Torre M, Wen PY, Iorgulescu JB. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. Neurooncol Pract 10(2):126-131, 2023. e-Pub 2023. PMID: 36970171.
19. Datta M, Chatterjee S, Perez EM, Gritsch S, Roberge S, Duquette M, Chen IX, Naxerova K, Kumar AS, Ghosh M, Emblem KE, Ng MR, Ho WW, Kumar P, Krishnan S, Dong X, Speranza MC, Neagu MR, Iorgulescu JB, Huang RY, Youssef G, Reardon DA, Sharpe AH, Freeman GJ, Suvà ML, Xu L, Jain RK. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proceedings of the National Academy of Sciences of the United States of America 120(6):e2219199120, 2023. e-Pub 2023. PMID: 36724255.
20. Neff C, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS, Ostrom QT, Iorgulescu JB. Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States. Neurooncol Pract 10(1):24-33, 2023. e-Pub 2023. PMID: 36659967.
21. Iorgulescu, JB, Ruthen, NG, Ahn, R, Panagioti, E, Gokhale, PC, Neagu, MR, Speranza, MC, Eschle, BK, Soroko, KM, Piranlioglu, R, Datta, M, Krishnan, S, Yates, KB, Baker, GJ, Jain, RK, Suvà, ML, Neuberg, D, White, F, Antonio Chiocca, E, Freeman, GJ, Sharpe, AH, Wu, C, Reardon, DA. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. Frontiers in immunology 14, 2023. e-Pub 2023. PMID: 38213329.
22. Gutierrez C, Ogino S, Meyerhardt JA, Iorgulescu JB. The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States. JCO Precis Oncol 7:e2200179, 2023. e-Pub 2023. PMID: 36716414.
23. Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite KA, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol 24(11):1989-2000, 2022. e-Pub 2022. PMID: 35460555.
24. Liu S, Iorgulescu JB, Li S, Borji M, Barrera-Lopez IA, Shanmugam V, Lyu H, Morriss JW, Garcia ZN, Murray E, Reardon DA, Yoon CH, Braun DA, Livak KJ, Wu CJ, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 55(10):1940-1952.e5, 2022. e-Pub 2022. PMID: 36223726.
25. Papke DJ, Lindeman NI, Schrag D, Iorgulescu JB. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 31(9):1746-1751, 2022. e-Pub 2022. PMID: 35767976.
26. Backlund CM, Holden RL, Moynihan KD, Garafola D, Farquhar C, Mehta NK, Maiorino L, Pham S, Iorgulescu JB, Reardon DA, Wu CJ, Pentelute BL, Irvine DJ. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A 119(32):e2204078119, 2022. e-Pub 2022. PMID: 35914154.
27. Lamba N, Ott PA, Iorgulescu JB. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era. JAMA Netw Open 5(8):e2225459, 2022. e-Pub 2022. PMID: 36006646.
28. Lee PC, Klaeger S, Le PM, Korthauer K, Cheng J, Ananthapadmanabhan V, Frost TC, Stevens JD, Wong AY, Iorgulescu JB, Tarren AY, Chea VA, Carulli IP, Lemvigh CK, Pedersen CB, Gartin AK, Sarkizova S, Wright KT, Li LW, Nomburg J, Li S, Huang T, Liu X, Pomerance L, Doherty LM, Apffel AM, Wallace LJ, Rachimi S, Felt KD, Wolff JO, Witten E, Zhang W, Neuberg D, Lane WJ, Zhang G, Olsen LR, Thakuria M, Rodig SJ, Clauser KR, Starrett GJ, Doench JG, Buhrlage SJ, Carr SA, DeCaprio JA, Wu CJ, Keskin DB. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. Journal of Clinical Investigation 132(13), 2022. e-Pub 2022. PMID: 35775490.
29. Lim-Fat MJ, Youssef GC, Touat M, Iorgulescu JB, Whorral S, Allen M, Rahman R, Chukwueke U, McFaline-Figueroa JR, Nayak L, Lee EQ, Batchelor TT, Arnaout O, Peruzzi PP, Chiocca EA, Reardon DA, Meredith D, Santagata S, Beroukhim R, Bi WL, Ligon KL, Wen PY. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol 24(7):1140-1149, 2022. e-Pub 2022. PMID: 34878541.
30. Lamba N, McAvoy M, Kavouridis VK, Smith TR, Touat M, Reardon DA, Iorgulescu JB. Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation. Neuro-Oncology Practice 9(3):201-207, 2022. e-Pub 2022. PMID: 35601971.
31. Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 605(7910):532-538, 2022. e-Pub 2022. PMID: 35508657.
32. Kavouridis VK, Ligon KL, Wen PY, Iorgulescu JB. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. J Neurooncol 158(1):111-116, 2022. e-Pub 2022. PMID: 35474499.
33. Castellanos LE, Gutierrez C, Smith T, Laws ER, Iorgulescu JB. Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification. Pituitary 25(1):201-209, 2022. e-Pub 2022. PMID: 34580820.
34. Lamba N, Groves A, Torre M, Yeo KK, Iorgulescu JB. The epidemiology of primary and metastatic brain tumors in infancy through childhood. J Neurooncol 156(2):419-429, 2022. e-Pub 2022. PMID: 35037155.
35. Gartland RM, Myers LC, Iorgulescu JB, Nguyen AT, Yu-Moe CW, Falcone B, Mitchell R, Kachalia A, Mort E. Body of Evidence: Do Autopsy Findings Impact Medical Malpractice Claim Outcomes?. J Patient Saf 17(8):576-582, 2021. e-Pub 2021. PMID: 32209947.
36. Boaro A, Kavouridis VK, Siddi F, Mezzalira E, Harary M, Iorgulescu JB, Reardon DA, Smith TR. Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. Acta Neurochir (Wien) 163(7):1883-1894, 2021. e-Pub 2021. PMID: 33871698.
37. Castellanos LE, Misra M, Smith TR, Laws ER, Iorgulescu JB. The epidemiology and management patterns of pediatric pituitary tumors in the United States. Pituitary 24(3):412-419, 2021. e-Pub 2021. PMID: 33433891.
38. Lim-Fat MJ, Song KW, Iorgulescu JB, Andersen BM, Forst DA, Jordan JT, Gerstner ER, Reardon DA, Wen PY, Arrillaga-Romany I. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol 152(3):515-522, 2021. e-Pub 2021. PMID: 33646525.
39. Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27(3):515-525, 2021. e-Pub 2021. PMID: 33479501.
40. Iorgulescu JB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK, Soroko KM, Chhoeu C, Knott A, Gao Y, Lim-Fat MJ, Baker GJ, Bonal DM, Nguyen QD, Grant GRL, Ligon KL, Sorger PK, Chiocca EA, Anderson AC, Kirschmeier PT, Sharpe AH, Freeman GJ, Reardon DA. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res 27(1):276-287, 2021. e-Pub 2021. PMID: 33239433.
41. Chen X, Lim-Fat MJ, Qin L, Li A, Bryant A, Bay CP, Gao L, Miskin N, Liu Z, Iorgulescu JB, Xu X, Reardon DA, Young GS. A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. Front Oncol 11:679331, 2021. e-Pub 2021. PMID: 34249718.
42. Lamba N, Chukwueke UN, Smith TR, Ligon KL, Aizer A, Reardon DA, Iorgulescu JB. Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol 6(12):1972-1974, 2020. e-Pub 2020. PMID: 33090181.
43. Harary M, Tung JK, Sood S, Corrales CE, Smith T, Iorgulescu JB. Benign purely intraosseous meningioma of the skull: Diagnosis and surgical outcomes. J Clin Neurosci 82(Pt A):36-42, 2020. e-Pub 2020. PMID: 33317736.
44. Gupta S, Iorgulescu JB, Hoffman S, Catalino M, Bernstock JD, Chua M, Segar DJ, Fandino LB, Laws ER, Smith TR. The diagnosis and management of primary and iatrogenic soft tissue sarcomas of the sella. Pituitary 23(5):558-572, 2020. e-Pub 2020. PMID: 32613388.
45. Hulsbergen AFC, Mammi M, Nagtegaal SHJ, Lak AM, Kavouridis V, Smith TR, Iorgulescu JB, Mekary RA, Verhoeff JJC, Broekman MLD, Phillips JG. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. Int J Radiat Oncol Biol Phys 108(1):258-267, 2020. e-Pub 2020. PMID: 32335185.
46. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580(7804):517-523, 2020. e-Pub 2020. PMID: 32322066.
47. Harary M, Kavouridis VK, Torre M, Zaidi HA, Chukwueke UN, Reardon DA, Smith TR, Iorgulescu JB. Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol 22(3):369-380, 2020. e-Pub 2020. PMID: 31538193.
48. Helgager J, Pytel P, Vasudevaraja V, Lee EQ, Snuderl M, Iorgulescu JB, Ligon KL. WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923883.
49. Kavouridis VK, Boaro A, Dorr J, Cho EY, Iorgulescu JB, Reardon DA, Arnaout O, Smith TR. Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg:1-11, 2019. e-Pub 2019. PMID: 31653812.
50. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
51. Kavouridis VK, Harary M, Hulsbergen AFC, Lo YT, Reardon DA, Aizer AA, Iorgulescu JB, Smith TR. Survival and prognostic factors in surgically treated brain metastases. J Neurooncol 143(2):359-367, 2019. e-Pub 2019. PMID: 30989623.
52. Iorgulescu JB, Torre M, Harary M, Smith TR, Aizer AA, Reardon DA, Barnholtz-Sloan JS, Perry A. The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res 25(8):2656-2663, 2019. e-Pub 2019. PMID: 30635340.
53. Gupta S, Ahmed AK, Bi WL, Dawood HY, Iorgulescu JB, Corrales CE, Dunn IF, Smith TR. Predicting Readmission and Reoperation for Benign Cranial Nerve Neoplasms: A Nationwide Analysis. World Neurosurg 121:e223-e229, 2019. e-Pub 2019. PMID: 30261394.
54. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234-239, 2019. e-Pub 2019. PMID: 30568305.
55. Iorgulescu JB, Freedman RA, Lester SC, Mittendorf EA, Brock JE. 21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32457931.
56. Iorgulescu JB, Ferris S, Agarwal A, Casavilca Zambrano S, Hill DA, Schmidt R, Perry A. Non-meningothelial meningeal tumours with meningioangiomatosis-like pattern of spread. Neuropathol Appl Neurobiol 44(7):743-746, 2018. e-Pub 2018. PMID: 29495087.
57. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother 67(12):1833-1844, 2018. e-Pub 2018. PMID: 30191256.
58. Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res 6(9):1039-1045, 2018. e-Pub 2018. PMID: 30002157.
59. Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol 135(4):635-638, 2018. e-Pub 2018. PMID: 29435664.
60. Zuckerman SL, Kreines F, Powers A, Iorgulescu JB, Elder JB, Bilsky MH, Laufer I. Stabilization of Tumor-Associated Craniovertebral Junction Instability: Indications, Operative Variables, and Outcomes. Neurosurgery 81(2):251-258, 2017. e-Pub 2017. PMID: 28368478.
61. Maggio DM, Singh A, Iorgulescu JB, Bleicher DH, Ghosh M, Lopez MM, Tuesta LM, Flora G, Dietrich WD, Pearse DD. Identifying the Long-Term Role of Inducible Nitric Oxide Synthase after Contusive Spinal Cord Injury Using a Transgenic Mouse Model. Int J Mol Sci 18(2), 2017. e-Pub 2017. PMID: 28125047.
62. Karhade AV, Fandino L, Gupta S, Cote DJ, Iorgulescu JB, Broekman ML, Aglio LS, Dunn IF, Smith TR. Impact of operative length on post-operative complications in meningioma surgery: a NSQIP analysis. J Neurooncol 131(1):59-67, 2017. e-Pub 2017. PMID: 27864707.
63. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res 22(19):4786-4796, 2016. e-Pub 2016. PMID: 27154916.
64. Iorgulescu JB, Ivan ME, Safaee M, Parsa AT. The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors. J Neuroimmunol 290:103-8, 2016. e-Pub 2016. PMID: 26711578.
65. McCrea HJ, Bander ED, Venn RA, Reiner AS, Iorgulescu JB, Puchi LA, Schaefer PM, Cederquist G, Greenfield JP. Sex, Age, Anatomic Location, and Extent of Resection Influence Outcomes in Children With High-grade Glioma. Neurosurgery 77(3):443-52; discussion 452-3, 2015. e-Pub 2015. PMID: 26083157.
66. Walcott BP, Iorgulescu JB, Stapleton CJ, Kamel H. Incidence, Timing, and Predictors of Delayed Shunting for Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care 23(1):54-8, 2015. e-Pub 2015. PMID: 25519720.
67. Luther N, Iorgulescu JB, Geannette C, Gebhard H, Saleh T, Tsiouris AJ, Härtl R. Comparison of navigated versus non-navigated pedicle screw placement in 260 patients and 1434 screws: screw accuracy, screw size, and the complexity of surgery. J Spinal Disord Tech 28(5):E298-303, 2015. e-Pub 2015. PMID: 23511642.
68. Moussazadeh N, Kulwin C, Anand VK, Ting JY, Gamss C, Iorgulescu JB, Tsiouris AJ, Cohen-Gadol AA, Schwartz TH. Endoscopic endonasal resection of skull base chondrosarcomas: technique and early results. J Neurosurg 122(4):735-42, 2015. e-Pub 2015. PMID: 25594323.
69. Iorgulescu JB, Patel SP, Louro J, Andrade CM, Sanchez AR, Pearse DD. Acute Putrescine Supplementation with Schwann Cell Implantation Improves Sensory and Serotonergic Axon Growth and Functional Recovery in Spinal Cord Injured Rats. Neural Plast 2015:186385, 2015. e-Pub 2015. PMID: 26550496.
70. Amankulor NM, Xu R, Iorgulescu JB, Chapman T, Reiner AS, Riedel E, Lis E, Yamada Y, Bilsky M, Laufer I. The incidence and patterns of hardware failure after separation surgery in patients with spinal metastatic tumors. Spine J 14(9):1850-9, 2014. e-Pub 2014. PMID: 24216397.
71. Iorgulescu JB, Laufer I, Hameed M, Boland P, Yamada Y, Lis E, Bilsky M. Benign notochordal cell tumors of the spine: natural history of 8 patients with histologically confirmed lesions. Neurosurgery 73(3):411-6, 2013. e-Pub 2013. PMID: 23719057.
72. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, Cox BW, Yamada Y, Bilsky MH. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18(3):207-14, 2013. e-Pub 2013. PMID: 23339593.
73. Komotar RJ, Iorgulescu JB, Raper DM, Holland EC, Beal K, Bilsky MH, Brennan CW, Tabar V, Sherman JH, Yamada Y, Gutin PH. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 117(4):679-86, 2012. e-Pub 2012. PMID: 22920955.
74. Luther N, Rubens E, Sethi N, Kandula P, Labar DR, Harden C, Perrine K, Christos PJ, Iorgulescu JB, Lancman G, Schaul NS, Kolesnik DV, Nouri S, Dawson A, Tsiouris AJ, Schwartz TH. The value of intraoperative electrocorticography in surgical decision making for temporal lobe epilepsy with normal MRI. Epilepsia 52(5):941-8, 2011. e-Pub 2011. PMID: 21480886.
75. Pearse DD, Tian RX, Nigro J, Iorgulescu JB, Puzis L, Jaimes EA. Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. Am J Physiol Renal Physiol 294(5):F1094-100, 2008. e-Pub 2008. PMID: 18337545.

Review Articles

1. Iorgulescu, JB, Medeiros, LJ, Patel, KP. Predictive and prognostic molecular biomarkers in lymphomas. Pathology 56(2):239-258, 2024. e-Pub 2024. PMID: 38216400.
2. Price, M, Ryan, K, Shoaf, ML, Neff, C, Iorgulescu, JB, Landi, D, Cioffi, G, Waite, K, Kruchko, C, Barnholtz-Sloan, JS, Ostrom, QT. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015–2019. Neuro-Oncology Practice 11(1):5-25, 2024. e-Pub 2024. PMID: 38222052.
3. Yearley AG, Iorgulescu JB, Chiocca EA, Peruzzi PP, Smith TR, Reardon DA, Mooney MA. The current state of glioma data registries. Neurooncol Adv 4(1):vdac099, 2022. e-Pub 2022. PMID: 36196363.
4. Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol 18(4):244-256, 2021. e-Pub 2021. PMID: 33277626.
5. Harary M, Reardon DA, Iorgulescu JB. Efficacy and safety of immune checkpoint blockade for brain metastases. CNS Oncol 8(2):CNS33, 2019. e-Pub 2019. PMID: 30854898.
6. Iorgulescu JB, Braun D, Oliveira G, Keskin DB, Wu CJ. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10(1):87, 2018. e-Pub 2018. PMID: 30466478.
7. Giantini Larsen AM, Cote DJ, Zaidi HA, Bi WL, Schmitt PJ, Iorgulescu JB, Miller MB, Smith TR, Lopes MB, Jane JA, Laws ER. Spindle cell oncocytoma of the pituitary gland. J Neurosurg 131(2):517-525, 2018. e-Pub 2018. PMID: 30485213.
8. Abd-El-Barr MM, Huang KT, Moses ZB, Iorgulescu JB, Chi JH. Recent advances in intradural spinal tumors. Neuro Oncol 20(6):729-742, 2018. e-Pub 2018. PMID: 29216380.
9. Ivan ME, Iorgulescu JB, El-Sayed I, McDermott MW, Parsa AT, Pletcher SD, Jahangiri A, Wagner J, Aghi MK. Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. J Clin Neurosci 22(1):48-54, 2015. e-Pub 2015. PMID: 25439754.
10. Vera E, Iorgulescu JB, Raper DM, Madhavan K, Lally BE, Morcos J, Elhammady S, Sherman J, Komotar RJ. A review of stereotactic radiosurgery practice in the management of skull base meningiomas. J Neurol Surg B Skull Base 75(3):152-8, 2014. e-Pub 2014. PMID: 25072008.
11. Siu A, Wind JJ, Iorgulescu JB, Chan TA, Yamada Y, Sherman JH. Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. Acta Neurochir (Wien) 154(2):191-201; discussion 201, 2012. e-Pub 2012. PMID: 22130634.
12. Shah AH, Madhavan K, Heros D, Raper DM, Iorgulescu JB, Lally BE, Komotar RJ. The management of incidental low-grade gliomas using magnetic resonance imaging: systematic review and optimal treatment paradigm. Neurosurg Focus 31(6):E12, 2011. e-Pub 2011. PMID: 22133169.

Other Articles

1. Komotar RJ, Raper DM, Starke RM, Iorgulescu JB, Gutin PH Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg 115(3):483-90, 2011. PMID: 21639698.

Editorials

1. Hechtman, JF, Baskovich, B, Fussell, A, Geiersbach, KB, Iorgulescu, JB, Sirohi, D, Snow, AN, Sidiropoulos, N. Charting the Genomic Frontier. Journal of Molecular Diagnostics 27(1):6-11, 2025. PMID: 39722285.
2. Shi Y, Iorgulescu JB, Valladao S, Atibalentja DF. Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology. JCO Precis Oncol 8:e2400068, 2024. PMID: 38815181.
3. Iorgulescu JB, Reardon DA, Chiocca EA, Wu CJ. Immunotherapy for glioblastoma: going viral. Nat Med 24(8):1094-1096, 2018. PMID: 30082860.

Letters to the Editor

1. Neff, C, Price, M, Cioffi, G, Waite, K, Kruchko, C, Iorgulescu, JB, Barnholtz-Sloan, J, Ostrom, QT. The impact of the COVID-19 pandemic on treatment patterns in glioblastoma. Neuro-oncology 26: 581-583, 2024.
2. Iorgulescu JB. Reporting of Immunotherapy and Biologic Therapy in the National Cancer Database. JAMA Oncol 9: 1003, 2023.